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A B S T R A C T
CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-
positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease
progression following endocrine therapy. Polypharmacy is a well-known problem in advanced cancer causing
potential drug-drug interactions (DDIs), which, in turn, may limit the therapeutic value of CDK4/6 inhibitors.
Therefore, understanding the mechanisms underlying potential DDIs in patients taking CDK4/6 inhibitors may
be useful in decision-making processes and represent an important step towards treatment personalization. The
present review is aimed at describing the potential DDIs that might occur in breast cancer patients receiving
CDK4/6 inhibitors based on direct evidence from the literature and mechanistic considerations tailored on
specific class of drugs used in combination.
Introduction
Clinical pharmacology of CDK4/6 inhibitors at a glance
Pharmacodynamics
CDK4/6 inhibitors, namely palbociclib, ribociclib and abemaciclib,
belong to a new class of anticancer drugs used for the treatment of
patients with hormone receptor (HR)-positive and human epidermal
growth factor receptor 2 (HER2)-negative breast cancer. Studies on the
structure-activity relationship suggest that the presence of the 2-amino-
pyridine group and the piperazine ring (Fig. 1) are important molecular
determinants for ATP-competitive inhibition and CDK4/6 selectivity
[1]. Abemaciclib has the highest CDK4/CDK6 selectivity ratio within
the class and the unique ability to target CDK9 at clinically relevant
concentrations [2]. These properties may account, at least partially, for
single-agent activity of abemaciclib in breast cancer patients [3],
whereas the other CDK4/6 inhibitors showed comparable efficacy in
combination with hormonal therapy [4]. CDK4/6 inhibitors can also
modulate the tumor microenvironment leading to immune cell activa-
tion and tumor clearance. This mainly occurs trough an increased ex-
pression of genes associated with inflammatory T-cell phenotype, a
reduction of regulatory T cell activity, and an activation of mechanisms
that favor antigen processing for MHC class II presentation [5–7].
Pharmacokinetics
Pharmacokinetics of CDK4/6 inhibitors is depicted schematically in
Fig. 2 and parameters are reported in Table 1. Palbociclib is adminis-
tered orally at 125mg once daily by a 3 weeks on/1 week off schedule,
in combination with an aromatase inhibitor (as initial therapy in
postmenopausal women) or fulvestrant (in women who have received
prior endocrine therapy) [4]. Food has been reported to reduce phar-
macokinetic variability of palbociclib [8,9] as well as the impact of
DDIs when concomitant administration of proton-pump inhibitors is
required [10]. Drug metabolism occurs by CYP3A and SULT2A1, and
the high volume of distribution (Vd) of 2793 L indicates substantial
tissue binding [9]. Penetration of palbociclib into the central nervous
system may be limited to some extent by efflux transporters (P-gp and
BCRP) at the blood-brain barrier level [11,12]. Renal excretion is a
minor route of elimination with a mean of 1.8% of unchanged drug
found in urine and the elimination half-life (t1/2) of palbociclib (about
26 h) is consistent with the once-daily schedule [9].
Ribociclib is used in combination with an aromatase inhibitor, as
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initial therapy for postmenopausal women with HR+ HER2− ad-
vanced breast cancer [4]. Overall exposure of a single oral dose of
600mg in healthy volunteers does not significantly change in fed versus
fasted states [13]. Furthermore, there is no impact of gastric pH-al-
tering agents on drug absorption [14]. Ribociclib is rapidly absorbed
with a time to maximum plasma concentration (Tmax) of 1 to 5 h and
daily administration is justified by a t1/2 of 33 to 42 h (Table 1). Ri-
bociclib undergoes extensive hepatic metabolism mediated by CYP3A4
and the main active metabolite (LEQ803) accounts for approximately
10% of the parent drug [15].
Abemaciclib is administered twice daily at 150mg in combination
with fulvestrant or at 200mg as monotherapy. Selection of these dose
levels was supported by the clinical dose-response relationship for
target engagement and the correlation of p-Rb suppression to clinical
activity. Drug doses can be scaled up or down depending on clinical
evidence of efficacy and/or toxicity [16]. Data from a phase I trial
demonstrated that abemaciclib dose adjustments are not required for
adult patients of different sex, age, or body weight [16]. The absolute
bioavailability of abemaciclib after a single oral dose of 200mg is 45%
and the median Tmax ranges from 4 to 6 h (Table 1). The AUC values of
abemaciclib and its active metabolites increase by 9% when adminis-
tered with a high-fat meal in healthy subjects. Abemaciclib is ex-
tensively metabolized by CYP3A4 with formation of equipotent active
metabolites [17]. The Vd is approximately 690 L. Improved central
nervous system penetration has been demonstrated for abemaciclib
with concentrations of parent drug and active metabolites in cere-
brospinal fluid comparable to unbound plasma concentrations [12,18].
Approximately 81% of the dose of abemaciclib is eliminated in feces as
metabolites and the elimination t1/2 is 18.3 h, which is consistent with
the twice-daily schedule used in breast cancer (Table 1).
Fig. 1. Chemical structures of CDK4/6 inhibitors [58].
Fig. 2. Pharmacokinetic overview of CDK4/6 inhibitors. Drugs are administered by oral route and, after absorption from the gastrointestinal tract, they can reach the
systemic circulation through the portal system. Drugs undergo extensive hepatic metabolism mediated mainly by the CYP3A4 isoform. Tissue distribution is in-
fluenced by plasma protein binding and penetration into the central nervous system (CNS) depends on drug lipophilicity. Drug elimination mainly occurs through
biliary excretion, whereas renal excretion is negligible. The metabolism of CDK4/6 inhibitors can be altered by concomitantly administered second drugs (D2) with
possible clinical consequences.
Table 1
Comparison of key pharmacokinetic characteristics of CDK4/6 inhibitors.
Palbociclib Ribociclib Abemaciclib
Dose (mg) 125 q.d. 600 q.d. 200 b.i.d.
Schedule 3weeks on/1 week off 3weeks on/1 week off Continuous
Metabolism CYP3A and SULT2A1 CYP3A4 CYP3A4
Active metabolites No Yes (LEQ803, CCI284) Yes
Cmax (ng/ml)* 52 ∼1000 298
Tmax (h) 7 ∼5 8
t1/2 (h) 25.9 32.6 17–38
Vd (l) 2793 1090 690.3
AUC (ng/mlxh) 299# ∼20,000∞ 5520
CNS penetration + NA +++
NA: not available. References [9,15].
* First cycle day 1.
# AUC0-10.
∞ AUC0-24.
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Safety
CDK4/6 inhibitors induce hematological adverse events (Table 2).
In particular, neutropenia represents the main dose-limiting toxicity for
this class of drugs and it is most frequently observed in patients treated
with palbociclib or ribociclib [19]. Neutropenia induced by CDK4/6
inhibitors is dose-dependent, rapidly reversible, usually not associated
with febrile neutropenia, and manageable by dose delay or reduction
[19]. This appears to be in line with evidence showing bone marrow
suppression through cell cycle arrest without apoptosis at clinically
relevant concentrations of palbociclib, with resumed proliferation fol-
lowing drug withdrawal [20]. These findings also support the inter-
mittent dosing regimen for palbociclib and ribociclib, which provides
time for bone marrow cells to recover during the 1-week treatment-free
period. Due to a lower incidence of neutropenia on abemaciclib com-
pared to palbociclib or ribociclib, abemaciclib can be given on a con-
tinuous dosing schedule [21].
The incidence of all-grade gastrointestinal (GI) toxicities is higher in
patients treated with abemaciclib than in patients given palbociclib or
ribociclib, although high-grade (3–4) events are relatively uncommon
(Table 2) [22]. GI adverse drug reactions are generally well controlled
by standard antiemetic (e.g., metoclopramide, serotonin 5-HT3 an-
tagonists), while the prophylactic administration of loperamide is re-
commended to prevent diarrhea in patient treated with abemaciclib
[23]. Fatigue, alopecia and stomatitis have also been reported among
patients treated with this class of drugs [24].
Treatment-related QTc interval prolongation on ribociclib was ob-
served in patients with Rb positive advanced solid tumors or lym-
phomas [15] (Table 2). Such an effect is generally asymptomatic, re-
versible upon drug cessation, and depends on the administered dose,
occurring in 9% of patients treated with 600mg/day 3-weeks on/1-
week off and in 33% of those receiving higher ribociclib doses [15].
Patients receiving ribociclib therefore undergo electrocardiograms and
electrolytes monitoring prior to initiation of treatment and during
follow-up. Furthermore, the risk of an additive adverse reaction should
be carefully taken into account in ribociclib-treated patients having
other conditions associated to QTc interval prolongation [25]. The risk
of Torsade de pointes (TdP) does not seem to be a class effect since no
QTc prolongation events were observed in patients treated with abe-
maciclib or palbociclib [26]. The mechanism of drug-induced QTc
prolongation involves the human ether-a-go-go-related gene (hERG)
that encodes the pore-forming subunit of the rapidly activating delayed
rectifier potassium channel (IKr), which is important for cardiac re-
polarization. Dysfunction of hERG causes long QT syndrome and
sudden death, which occur in patients with cardiac ischemia [27]. All
drugs known to prolong the QT interval were shown to block the hERG
channels in cardiac myocytes. However, the chemical structures of
these drugs can be very different [28].
Potential DDIs in patients treated with CDK4/6 inhibitors
Pharmacokinetic-based DDIs
Pharmacokinetic interactions occur when two or more drugs are
substrates of the same enzymes/transporters involved in their absorp-
tion, metabolism, disposition and/or excretion. These types of DDIs can
substantially affect the exposure levels of drugs with the consequent
potential increase of significant type A (augmented) or F (failure) ADRs
[29] (Fig. 2).
CYP3A4-based DDIs
CYP3A4 plays a pivotal role in metabolism of CDK4/6 inhibitors
and the low substrate specificity makes it a susceptible target for re-
versible or irreversible inhibition by a large number of drugs (Fig. 2).
The irreversible CYP3A4 inhibition (i.e., inactivation by the formation
of metabolic intermediates that bind tightly to the enzyme) more fre-
quently causes DDIs than reversible inhibition, as the inactivated
CYP3A4 has to be replaced by newly synthesized protein [30]. For in-
stance, when erythromycin or clarithromycin is co-administered with
terfenadine, astemizole, or pimozide, patients may experience TdP
[30], whereas older people taking CYP3A4-metabolized statins and
clarithromycin or erythromycin were hospitalized more frequently for
rhabdomyolysis and acute kidney injury [31].
Patients experiencing neutropenia after treatment with anticancer
agents may benefit most from antibiotic, antifungal, and antiviral
prophylaxis [32]. However, caution is required in the presence of
multiple treatments and the choice of the antimicrobial agent should be
carefully evaluated. For instance, co-administration of CDK4/6 in-
hibitors with strong CYP3A inducers demonstrated to decrease plasma
concentrations of the CDK4/6 inhibitor leading to potential drug failure
[33]. A paradigmatic example of such a type of interaction has been
shown in healthy subjects, where the administration of rifampin was
associated to an 85% and 95% decrease in plasma AUC of palbociclib
and abemaciclib, respectively [33]. According to this, rifampin de-
creased the plasma exposure of palbociclib in healthy subjects by 85%
[21], suggesting that concomitant use of strong CYP3A inducers and
CDK4/6 inhibitors should be avoided in breast cancer patients and a
non-interacting alternative considered (Table 3).
The opposite scenario may occur in breast cancer patients treated
with strong CYP3A4 inhibitors (Fig. 2), which have been demonstrated
to increase the pharmacokinetic exposure of CDK4/6 inhibitors to a
Table 2
Incidence of adverse drug reactions (ADRs) with CDK4/6 inhibitors.
ADRs (%) Palbociclib Ribociclib Abemaciclib
Any grade (Grade 3/4) Any grade (Grade 3/4) Any grade (Grade 3/4)
Neutropenia 81 65 74 58 41–46 22–27
Febrile neutropenia 2 1 NR 1.5 <1 <1
Anemia 28 5 17–19 2–3 28–29 6–8
Leukopenia 45 27 27–33 13–21 21–28 8–10
Thrombocytopenia 19 2 9 NR 10–16 2–3
Diarrhea 19–26 0–4 29–35 1 81–90 9–20
Nausea 25–35 0–2 51.5 2.4 39–64 1–4.5
Vomiting 14 0–1 29 4 NR NR
Increased ALT 8 2 15–46 6–10 13–16 4–6
Increased ALT 9 3 13–44 5–7 12–15 2–3
Fatigue 37–39 2 36.5 2 40–65 2–13
QTc prolongation* NR 1 6.2 NR NR 1
NR: No evidence was reported.
* In the PALOMA-3 trial, only one patient experienced QT prolongation (SAE of grade 3), which resolved within 2 days. In MONARCH 1, only one patient
discontinued the treatment due to QT prolongation. References: [22,23,26,44].
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clinically meaningful extent, potentially leading to increased toxicity
[21]. For example, co-administration of clarithromycin has been re-
ported to increase abemaciclib AUC by 237% and Cmax by 30%, re-
spectively, and those of the total active metabolites by 119% and 7%,
respectively [33]. As a consequence, clarithromycin and abemaciclib
combination should be avoided or, alternatively, abemaciclib dose
should be reduced from 200 or 150mg to 100mg twice daily [17].
Accordingly, daily dose of palbociclib needs to be reduced from 125 to
75mg and that of ribociclib from 600 to 400mg, in the presence of
strong CYP3A4 inhibitors [21].
The time-dependent offset of CYP3A4 inhibition may account for
some serious adverse reactions associated with discontinuation of ir-
reversible inhibitors and immediate initiation of a second drug treat-
ment [30]. Therefore, it is important to apply an appropriate washout
period before giving the second potentially interacting drug. In case of
discontinuation, the CDK4/6 dose intensity should be returned to status
quo ante after 3–5 half-lives of the perpetrator drug only [21]. Another
feasible approach to mitigate the consequences of DDIs, while main-
taining the class effect may consist in using other members of the same
group of drugs having little or no effect on CYP3A4 activity. For ex-
ample, azithromycin has a negligible effect on CYP3A4 (i.e., it does not
inhibit CYP3A4 or increase blood concentrations of CYP3A4-metabo-
lized statins) and could be given to patients receiving CDK4/6 in-
hibitors in place of clarithromycin [31] (Table 3). Finally, it should be
noted that breast cancer patients treated with CDK4/6 inhibitors have a
very low risk to develop febrile neutropenia and, anti-pseudomonas β-
lactam agents, i.e., drugs proven not interacting with CYP3A4-meta-
bolized substrates [34], are the first choice treatment for high-risk pa-
tients who require hospitalization for intravenous antibiotic therapy
[32], in those uncommon cases of febrile neutropenia and risk of septic
shock.
Cancer patients who have persistent fever after a broad-spectrum
antibacterial regimen may also benefit from empirical antifungal
treatments. However, selection of a specific antifungal agent needs to
be carefully evaluated by taking into account that DDIs involving an-
tifungals are common during multiple treatments [32,35]. For example,
ketoconazole is predicted to increase the AUC of abemaciclib by up to
16-fold with potential toxicity; this combination should be therefore
avoided and non-interacting alternatives considered in patients re-
ceiving CDK4/6 inhibitors [17]. A possible alternative is represented by
echinocandins, which display a lower potential for DDIs [35]. Indeed,
they do not promote a marked inhibition of P450 activities in vitro and
the blood/plasma concentrations of concomitant CYP3A4-metabolized
drugs were not markedly affected by co-administration of echino-
candins in vivo [36]. This drug class could therefore represent a valid
alternative to azole derivatives in patients administered with CDK4/6
inhibitors.
Several lines of evidence indicate that immunosuppressed trans-
plant recipients and HIV-infected patients have a diminished incidence
of breast cancer relative to other malignancies [37]. Because of this,
patients having both HIV and breast cancer are very rare [37], sug-
gesting that co-administration of anti-HIV treatments and CDK4/6 in-
hibitors is uncommon in the real-life setting. However, the aggres-
siveness of breast cancer in the rare cases of HIV-positive women
justifies every effort to preserve the dose intensity of treatment [38].
Avoiding unexpected adverse drug reactions is important, especially
taking into account the current near-normal life expectancy for HIV-
positive patients. Potential concerns on the concomitant use of CDK4/6
inhibitors and antiretroviral drugs are discussed in the “Complex DDIs”
section below.
P-gp/BCRP-based DDIs
P-glycoprotein (P-gp) and BCRP (Breast Cancer Resistance Protein)
belong to the superfamily of ATP-binding cassette (ABC) transporters,
which play a pivotal role in absorption, distribution and elimination of
a large number of drugs [11,39]. P‐gp- and BCRP-based DDIs may
therefore have important clinical implications, particularly in terms of
intestinal absorption and distribution of drugs across the blood–brain
barrier (BBB) [40]. For example, in healthy volunteers, rifampin
treatment (600mg/d for 10 days) increased intestinal P-gp content by
3.5-fold and markedly reduced digoxin plasma concentrations after oral
administration [41]. Although no evidence has been provided in breast
cancer patients, CDK4/6 are substrates of P-gp [12] and rifampin-
mediated intestinal P-gp induction is expected to decrease CDK4/6
bioavailability after oral administration. However, the consequences of
P-gp induction by ripampicin on abemaciclib pharmacokinetics could
be more difficult to predict, since abemaciclib has been demonstrated to
inhibit P-gp and BCRP activities at clinically reachable concentrations
[39].
Increased bioavailability of CDK4/6 inhibitors can be expected in
the presence of antifungal azoles, namely isavuconazole, ketoconazole,
and itraconazole, as they are strong P-gp inhibitors [35]; in this case,
dose reduction of CDK4/6 inhibitors may be appropriate as well as the
use of non-interacting antifungal agents (Table 3).
In the blood-brain barrier, the presence of efflux transporters such
as P-gp and BCRP have been reported to limit the distribution into the
Table 3
Pharmacokinetic-based DDIs between CDK4/6 inhibitors and various drug classes. Red: potential increase of significant type A or F ADRs; yellow: potential increase
of moderate type A or F ADRs; green: no increase of type A or F ADRs. Legend: Cat: Category.
Mechanism Perpetrator drugs Risk of DDIs
Strength Likelihood Impact Cat.
CYP3A inhibition Clarithromycin, telithromycin Strong Intermediate High
Erythromycin Moderate Intermediate Intermediate
Azithromycin Weak Intermediate Low
Itraconazole, ketoconazole, posaconazole Strong Intermediate High
Fluconazole, voriconazole Moderate Intermediate Intermediate
Ritonavir Strong Very low High
Saquinavir Moderate Very low Intermediate
Diltiazem, verapamil Moderate Intermediate Intermediate
Fluoxetine, fluvoxamine Weak Intermediate Low
CYP3A induction Rifampin Strong Low High
Efavirenz Moderate Very low Intermediate
P-gp inhibition Isavuconazole, ketoconazole, itraconazole Strong Intermediate High
P-gp induction Rifampin Strong Intermediate High
Classification of DDIs is based on The Flockhart Table™. Strong inhibition:> 5-fold increase in the plasma AUC values or> 80% decrease in clearance of a victim
drug; moderate inhibition:> 2-fold increase in the plasma AUC values or 50–80% decrease in clearance of a victim drug; weak inhibition:> 1.25-fold but< 2-fold
increase in the plasma AUC values or 20–50% decrease in clearance of a victim drug [59]. Green box: no change; Yellow box: reduce the dose of CDK4/6 inhibitor or
consider alternative secondary drugs; Red box: avoid combination and consider alternative secondary drugs.
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central nervous system (CNS) of palbociclib compared to abemaciclib
[3,4]. Abemaciclib drug levels in the brain can be reached at lower
doses compared to palbociclib most probably because of the higher li-
pophilicity of abemaciclib (cLogP value of 5.5 and 2.7, respectively) [2]
as well as through the P-gp/ BCRP inhibitory effect of abemaciclib [39].
Antifungal azole can competitively interact with P-gp at the blood-brain
barrier level [42] in such a way to favor the CNS penetration of P-gp
substrates, including CDK4/6 inhibitors.
Pharmacodynamic-based DDIs
Pharmacodynamic interactions are usually characterized by over-
lapping on-target and/or off-target effects by two or more drugs con-
comitantly administered to a patient. They can involve either an ad-
ditive, synergistic, or antagonistic interaction that may favor or harm
the patient. Often the interaction is indirect and involves interference
with physiological mechanisms; indeed, if two drugs sharing the same
toxicological effect are given together, the resulting effect can be ad-
ditive [29].
A paradigmatic example of pharmacodynamic-based DDIs poten-
tially occurring in patients receiving CDK4/6 inhibitors derives from
the concomitant administration of ribociclib and heart rate-corrected
QT (QTc)-prolonging drugs. Although QT prolongation is usually con-
sidered necessary but not sufficient to induce TdP, an increased risk for
TdP may occur whenever QTc exceeds 500ms or a drug rapidly in-
creases QTc by>60–70ms [43]. In the MONALEESA-3 trial, QT in-
terval prolongation (any grade) was reported in 6.2% of patients re-
ceiving ribociclib plus fulvestrant, with 0.6% of them discontinuing
study treatment [44]. TdP and fatal ventricular arrhythmia, although
rare, might therefore occur in patients treated with ribociclib as a
consequence of additive effect by QTc-prolonging drugs (Table 4) and/
or other medical conditions (Table 5).
Drugs causing QT interval prolongation
Anticancer drugs. Preclinical and clinical investigation suggest that
tamoxifen may cause QT interval prolongation in humans by blocking
the rectifier potassium current [37,38]. Furthermore, 5-fluorouracil and
its pro-drug capecitabine [39,40] as well as anthracyclines [45] have
been reported to induce QT prolongation with TdP and ventricular
tachycardia in women with early breast cancer. A possible strategy to
avoid potential additive effects in patients pretreated with tamoxifen
and/or chemotherapy, is to initiate ribociclib treatment after five half-
lives of the previously discontinued drug. While such an approach
appears to be unfeasible for tamoxifen due to its long elimination half-
life (t1/2, 7 days), it could be feasible for epirubicin and 5-fluorouracil
(t1/2 of ∼30 h and 10min, respectively). Intensifying ECG monitoring
during follow-up or selecting alternative CDK4/6 inhibitors (i.e.,
abemaciclib or palbociclib) having little or no effects on QT interval
[26] may also be valid alternatives (Table 4).
Antiemetic drugs. Chemotherapy-induced nausea and vomiting is one of
the most common adverse effects of CDK4/6 inhibitors and 5-HT3-
receptor antagonists are frequently used to treat this adverse reaction.
Unfortunately, QT prolongation is a class effect of the 5-HT3-receptor
antagonists and caution is required when administering these drugs in
patients using ribociclib (Table 4). However, while conflicting evidence
on a possible risk of TdP has been provided for granisetron and
tropisetron, no significant change in QTc interval was observed for
palonosetron, a second-generation drug with higher affinity for 5-HT3
receptors and longer half-life than first-generation drugs [46]. Clinical
trials carried out using NK-1 receptor antagonists as single agents (e.g.,
aprepitant and fosaprepitant) or in combination schedules (i.e.,
netupitant plus palonosetron), suggest that this class of drugs is not
associated with a significant QTc interval prolongation. Therefore,
adoption of antiemetics with low risk of QT prolongation (e.g.,
palonosetron or NK-1 receptor antagonists) together with ECG
monitoring could be used as an alternative antiemetic strategy to
reduce the risk of arrhythmic events in breast cancer patients receiving
ribociclib [46].
Analgesic drugs. Opioid analgesics are a cornerstone of severe pain
treatment including cancer pain [47]. Several drugs in this class
endowed with a bi-phenyl ring structure (e.g., propoxyphene and
methadone) have an important QT prolongation potential [48,49],
while those which differ structurally (e.g., buprenorphine) has a less
potent QT prolonging effect. Furthermore, morphine does not
significantly change the QTc interval [48] and should be selected in
patients treated with ribociclib. Important to note, buprenorphine,
fentanyl and alfentanil could be used as a valid alternative to morphine
in opioid rotation in ribociclib-treated patients since no QTc
prolongation-related issues were reported for these drugs [48]. No
QTc effects were observed at supratherapeutic doses of the opioid/
nonopioid analgesics tramadol [50] and tapentadol [51].
Psychiatric drugs. Depression is common in cancer patients and, due to
the lack of efficacy data from head-to-head clinical comparison, the
safety profile is often used to guide the antidepressant selection [52]. In
case of breast cancer patients treated with ribociclib, clinicians should
Table 4
Predicted risk of torsade de pointes of various drug classes often used in breast
cancer patients during or before ribociclib.
Drug categories Risk of torsade de pointes
Likelihood Impact Cat.
Cancer





Granisetron, tropisetron High Intermediate




Methadone, oxycodone High High
Tramadol, ketorolac High Intermediate
Microbial infections
Erythromycin, clarithromycin Intermediate High
Azithromycin Intermediate Intermediate
Ciprofloxacin, levofloxacin, moxifloxacin Intermediate High






Propofol, sevoflurane Intermediate High
Psychiatric disorders
Citalopram, escitalopram Intermediate High
Venlafaxine Intermediate Intermediate
Paroxetine, fluoxetine, sertraline Intermediate Low
Chlorpromazine High High
Thioridazine Low High
Risk of Torsade de pointes is based on the likelihood that a DDIs can actually
occur in breast cancer patients receiving ribociclib, and on the QT prolongation
potential of perpetrator drugs [60]. Green box: no change; Yellow box: initiate
ribociclib dose after five half-lives of secondary drug discontinuation or, in-
tensify ECG and clinical monitoring or, consider alternative secondary drugs or
less arrhythmogenic CDK4/6 inhibitors; Red box: avoid combination and con-
sider alternative secondary drugs or less arrhythmogenic CDK4/6 inhibitors.
GERD: gastroesophageal reflux disease. NCI classification of QT interval pro-
longation (QTc, ms): grade 1 (450–480); grade 2 (481–500); grade 3 (> 501ms
on at least two separate electrocardiograms); grade 4 (> 501ms or a change
of> 60ms from baseline); torsades de pointes (polymorphic ventricular ta-
chycardia, or signs or symptoms of severe arrhythmia) [26].
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pay attention to antidepressants with QT prolongation potential,
particularly citalopram and escitalopram (Table 4).
Antimicrobial agents. Several antimicrobial agents have the potential to
induce clinically relevant QT prolongation effects (Table 4). Macrolides
can affect repolarization in the His-Purkinje tissue and the M cells in the
ventricular myocardium and such an effect appears to be related to the
rate of drug infusion [53]. Since azithromycin has been proved to be the
least likely macrolide to cause cardiac arrhythmias (Table 4) [53], this
drug should be used as a first choice in those ribociclib-treated patients
who required therapy with this class of drugs. Fluoroquinolones have
also been associated to QT interval prolongation with various levels of
evidence (Table 4). Particularly, fluconazole may cause prolongation of
QTc syndrome via a double mechanism consisting of the direct
inhibition of rectifier potassium current, the main repolarizing
current and disruption of hERG protein trafficking [54]. Combination
of ribociclib with antifungal azoles should be avoided and alternative
drugs should be used. Whenever azole treatment is strictly required,
voriconazole should be preferred and clinical/ECG monitoring carried
out in patients receiving ribociclib (Table 4).
Complex DDIs
Several lines of evidence indicate that a great number of DDIs may
often occur by two or more mechanisms acting in concert [29], which
makes the prediction of DDIs in patients treated with CDK4/6 inhibitors
more complex. For example, combination of fluoroquinolones and
azoles can be used as prophylaxis or treatment of infections in neu-
tropenic cancer patients [55]. Unfortunately, many of these drugs have
QTc prolonging potential [55] and the use of this combination should
be avoided in at-risk patients for long QT syndrome, including those
receiving ribociclib. Beside representing an additional risk factor for QT
prolongation per se, the torsadogenic potential of ribociclib may be
further increased as a consequence of azole-mediated CYP3A4 inhibi-
tion. The ability of antifungal azoles to competitively interact with P-gp
substrates [42] may represent another mechanism that could alter the
pharmacokinetics of CDK4/6 inhibitors.
Multiple mechanisms may also characterize potential clinical DDIs
between rifampicin and CDK4/6 inhibitors. Rifampin can affect other
physiological processes beside CYP3A4, including P-gp [41] and UGT
induction [56], that need to be considered as likely perpetrator me-
chanisms in patients receiving CDK4/6 inhibitors.
Drug metabolism may also increase the complexity of data inter-
pretation. For instance, the HIV protease inhibitor nelfinavir is pri-
marily metabolized by CYP2C19; this drug is capable of increasing
simvastatin plasma levels and the risk of rhabdomyolysis through its
metabolite, which strongly inhibits CYP3A4 [57].
Finally, the planned combination of antiretrovirals belonging to the
same drug class makes the clinical consequences of their interaction
with CDK4/6 inhibitors unpredictable. For instance, it has been re-
cognized that saquinavir has the lowest inhibition potency on CYP3A4
within the class and is expected to induce only modest changes in the
pharmacokinetics of CYP3A4 substrates. However, HIV treatment may
include ritonavir-boosted schedules to achieve higher sustained levels
of the second protease inhibitor and ritonavir/saquinavir has been
shown to strongly increase the exposure to simvastatin acid [57].
Conclusions and future perspectives
CDK4/6 inhibitors are innovative targeted drugs that have recently
enriched the treatment landscape of breast cancer. Polypharmacy is
very common in cancer patients and DDIs can affect the pharmacoki-
netics and/or pharmacodynamics of these drugs thus adding complexity
to the optimal management of subjects taking CDK4/6 inhibitors, by
exposing patients to under-treatment or severe adverse drug reactions.
As regards the latter, it is important to note that although drugs be-
longing to this class have similar clinical efficacy, their toxicity profile
is quite different. In particular, hematological toxicity and diarrhea are
respectively less and more frequent in patients taking abemaciclib than
palbociclib or ribociclib, whereas incidence of liver function abnorm-
alities is higher for ribociclib than palbociclib or abemaciclib.
Furthermore, the risk of an additive adverse reaction should be taken
into account particularly in ribociclib-treated patients having other
conditions predicted to prolong the QTc interval. Understanding the
mechanisms of DDI, together with the integrated knowledge of patient/
drug-specific characteristics, may therefore represent the basis for op-
timal therapeutic decision-making in patients receiving CDK4/6 in-
hibitors. Owing to the complexity of treatment personalization, a
multidisciplinary approach involving clinical pharmacologists and on-
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